본문으로 건너뛰기
← 뒤로

Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.

1/5 보강
Blood advances 📖 저널 OA 99.1% 2021: 1/1 OA 2025: 59/59 OA 2026: 165/167 OA 2021~2026 2026 Vol.10(4) p. 1400-1404 OA
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
18 patients with PCL (peripheral blood, n = 10; bone marrow, n = 8) and 1742 multiple myeloma (MM) samples.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Translocations occurred in 11 (61.1%) patients with PCL; IGH::CCND1 and IGH::MYC were more frequent in PCL than in MM (22% vs 14%, P = not significant and 11% vs 1%, P< .05, respectively). Druggable aberrations in BRAF, CCND1, PIK3R1, and RAS may be targeted in biomarker-driven therapeutic clinical trials.

Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan S

📝 환자 설명용 한 줄

Plasma cell leukemia (PCL) is rare and aggressive.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 10
  • p-value P< .05

이 논문을 인용하기

↓ .bib ↓ .ris
APA Mohan M, Danziger N, et al. (2026). Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.. Blood advances, 10(4), 1400-1404. https://doi.org/10.1182/bloodadvances.2025018342
MLA Mohan M, et al.. "Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.." Blood advances, vol. 10, no. 4, 2026, pp. 1400-1404.
PMID 41411484 ↗

Abstract

Plasma cell leukemia (PCL) is rare and aggressive. Plasma cells from patients with PCL were examined using next-generation sequencing (NGS). We compared NGS data from 18 patients with PCL (peripheral blood, n = 10; bone marrow, n = 8) and 1742 multiple myeloma (MM) samples. Mutations of TP53, CCND1, and KRAS were commonly observed in both diseases. Alterations in DIS3 (17% vs 1%), CCND2 (22% vs 15%), PIK3R1 (6% vs 0%), and MAP3K1 (6% vs 2%) were more common in PCL than in MM (P< .05). Translocations occurred in 11 (61.1%) patients with PCL; IGH::CCND1 and IGH::MYC were more frequent in PCL than in MM (22% vs 14%, P = not significant and 11% vs 1%, P< .05, respectively). Druggable aberrations in BRAF, CCND1, PIK3R1, and RAS may be targeted in biomarker-driven therapeutic clinical trials.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (3)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기